In proof-of-concept studies, NNMT inhibitors (NNMTis) have demonstrated promise as potential treatments for obesity and obesity-related metabolic comorbidities (e.g., T2D, fatty liver)8,9,13. Here, NNMT is linked to type 2 diabetes mellitus.